<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00972114</url>
  </required_header>
  <id_info>
    <org_study_id>20090903</org_study_id>
    <nct_id>NCT00972114</nct_id>
  </id_info>
  <brief_title>CABG Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Ischemic Cardiomyopathy</brief_title>
  <official_title>Coronary Artery Bypass Graft Surgery Combined Pedicled Omentum Wrapped Autologous Atrial Tissue Patch Cardiomyoplasty for Patients With Ischemic Cardiomyopathy: a Prospective Randomized Controlled Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>China National Center for Cardiovascular Diseases</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>China National Center for Cardiovascular Diseases</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is in a phase I/II safety and efficacy study to evaluate the&#xD;
      clinical effect of coronary artery bypass graft (CABG) combined pedicled omentum wrapped&#xD;
      autologous atrial tissue patch cardiomyoplasty for patients with ischemic cardiomyopathy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a phase I/II, randomized controlled trial to evaluate the use of CABG combined&#xD;
      pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty for patients with&#xD;
      ischemic cardiomyopathy. The study hypothesis is that the combined surgical technique to&#xD;
      perform pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty as adjunct to&#xD;
      CABG, is safe to patients with severe ischemic heart failure and can improve regional&#xD;
      myocardial perfusion contractility, which resulting in improved systolic and diastolic left&#xD;
      ventricular function.&#xD;
&#xD;
      The primary object of this study will be to evaluate the safety and efficacy of this novel&#xD;
      combined surgical technique. The efficacy will be assessed changes in left ventricular&#xD;
      ejection fraction by MRI. The secondary endpoint of the study is to assess the effects of&#xD;
      this novel combined surgical technique on cardiac contractile function and functional&#xD;
      outcome. The effects will be assessed on the basis of clinical status and imaging rests in 6&#xD;
      month follow-up after enrollment. A maximum of 60 patients between 20 and 70 years will be&#xD;
      enrolled in the study. These participants will be randomized to receive CABG, pedicled&#xD;
      omentum graft combined CABG, or pedicled omentum graft autologous atrial tissue patch&#xD;
      cardiomyoplasty combined CABG. The objective evaluations will be performed at baseline and&#xD;
      during 6 months follow-up.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>October 2009</start_date>
  <completion_date type="Anticipated">December 2011</completion_date>
  <primary_completion_date type="Anticipated">June 2010</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety of CABG combined pedicled omentum wrapped autologous atrial tissue transplantation.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Changes in left ventricular ejection fraction (LVEF) by MRI.</measure>
    <time_frame>6 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Changes in LVEF by echocardiography.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in regional wall motion by MRI.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in regional wall motion by echocardiography.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Changes in fixed perfusion defect(s) by single photon emission computed tomography.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical improvements, including change in 6 minutes walk test, as determined by multiple measures.</measure>
    <time_frame>6 months</time_frame>
  </secondary_outcome>
  <number_of_arms>3</number_of_arms>
  <enrollment type="Anticipated">70</enrollment>
  <condition>Ischemic Cardiomyopathy</condition>
  <condition>Congestive Heart Failure</condition>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>CABG combined cardiomyoplasty</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG combined pedicled omentum graft</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coronary artery bypass graft surgery combined pedicled omentum graft</description>
  </arm_group>
  <arm_group>
    <arm_group_label>CABG alone</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Coronary artery bypass graft surgery alone</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG combined cardiomyoplasty</intervention_name>
    <description>coronary artery bypass graft surgery combined pedicled omentum wrapped autologous atrial tissue patch cardiomyoplasty</description>
    <arm_group_label>CABG combined cardiomyoplasty</arm_group_label>
    <other_name>CABG combined pedicled omentum graft</other_name>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG combined pedicled omentum graft</intervention_name>
    <description>Coronary artery bypass graft surgery combined pedicled omentum graft</description>
    <arm_group_label>CABG combined pedicled omentum graft</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>CABG alone</intervention_name>
    <description>Coronary artery bypass graft surgery alone</description>
    <arm_group_label>CABG alone</arm_group_label>
    <other_name>Coronary artery bypass graft surgery alone</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Male or female;&#xD;
&#xD;
          -  20-70 years old;&#xD;
&#xD;
          -  Ability to give informed consent;&#xD;
&#xD;
          -  Documented severe coronary heart disease, defined as at least 70% luminal diameter&#xD;
             narrowing of at least three major coronary artery, suited to CABG;&#xD;
&#xD;
          -  Left ventricular dysfunction (LVEF) less than or equal to 35%, measured by MRI or less&#xD;
             than or equal to 45%, measured by echocardiogram;&#xD;
&#xD;
          -  Presence of reversibility, as identified by single photon emission computed tomography&#xD;
             (SPECT) isotope protocol;&#xD;
&#xD;
          -  At least 3 months since last episode of myocardial infarction;&#xD;
&#xD;
          -  Without a history of abdominal operation and severe abdominal diseases;&#xD;
&#xD;
          -  Negative pregnancy test (in women with childbearing potential.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Pregnant or lactating;&#xD;
&#xD;
          -  A history of malignancy in the last 5 years excluding basal cell carcinoma, that has&#xD;
             been surgically removed, with proof of surgical clean margins;&#xD;
&#xD;
          -  a history of abdominal operation or severe abdominal diseases;&#xD;
&#xD;
          -  Positive test result for human immunodeficiency virus (HIV), hepatitis B, or hepatitis&#xD;
             C&#xD;
&#xD;
          -  Any condition requiring immunosuppressive medication;&#xD;
&#xD;
          -  Bleeding diathesis, defined as an international normalized ratio of at least 2.0 in&#xD;
             the absence of warfarin therapy;&#xD;
&#xD;
          -  Hepatic dysfunction, as defined as aspartate aminotransferase (AST) or alanine&#xD;
             aminotransferase (ALT) more than 1.5 times the upper limit of normal range prior to&#xD;
             study entry;&#xD;
&#xD;
          -  Chronic renal insufficiency, defined as a serum creatinine level greater than 2.5&#xD;
             mg/dL or requiring dialysis;&#xD;
&#xD;
          -  Leukocytes less than 4,000/µL or exceeding 10,000/µL;&#xD;
&#xD;
          -  Platelets less than 100,000/µL;&#xD;
&#xD;
          -  Hemoglobin less than 10 g/dL;&#xD;
&#xD;
          -  Chronic atrial fibrillation;&#xD;
&#xD;
          -  Less than 3 months since last episode of cerebral infarction;&#xD;
&#xD;
          -  Implantable cardioverter-defibrillator shock within 30 days of baseline consent, and&#xD;
             within 30 days of randomization;&#xD;
&#xD;
          -  Presence of ventricular tachycardia lasting 30 seconds or more on 24-hour Holter&#xD;
             monitor or electrocardiogram (ECG) performed during screening period;&#xD;
&#xD;
          -  Patients for whom it is impossible to perform both cardiac MRI;&#xD;
&#xD;
          -  Enrolled in an investigational device or drug study within the previous1 year;&#xD;
&#xD;
          -  Any other reason that the Clinical Supervisors or Clinical Researchers may have for&#xD;
             considering a case unsuitable for the study.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>20 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shengshou Hu, MD</last_name>
    <role>Study Director</role>
    <affiliation>National Center for Cardiovascular Diseases, China</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>China National Center for Cardiovascular Diseases, Cardiovascular Institute &amp; Fuwai Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jianfeng Hou, M.D., Ph.D.</last_name>
      <phone>+86 10 88398359</phone>
      <email>hjf2006111@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Institute of cardiovascular diseases &amp; Fuwai hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100037</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Shengshou Hu, MD</last_name>
      <phone>0086-10-8839-8359</phone>
      <email>shengshouhu@yahoo.com</email>
    </contact>
    <contact_backup>
      <last_name>Jianfeng Hou, MD, PhD</last_name>
      <phone>0086-10-8839-8359</phone>
      <email>hjf2006111@163.com</email>
    </contact_backup>
    <investigator>
      <last_name>Shengshou Hu, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>December 2009</verification_date>
  <study_first_submitted>September 3, 2009</study_first_submitted>
  <study_first_submitted_qc>September 3, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 4, 2009</study_first_posted>
  <last_update_submitted>December 9, 2009</last_update_submitted>
  <last_update_submitted_qc>December 9, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 10, 2009</last_update_posted>
  <responsible_party>
    <name_title>Shengshou Hu MD, FACC</name_title>
    <organization>China National Center for Cardiovascular Diseases</organization>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Cardiomyopathies</mesh_term>
    <mesh_term>Ischemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

